Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test
March 10, 2011
Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test
The test, from researchers at the Cyprus Institute of Neurology and Genetics, combines methylated DNA immunoprecipitation and quantitative real-time PCR, and has demonstrated 100 percent sensitivity and specificity.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quake Group Issued Patent for Detection of Fetal Aneuploidy with Next-Gen Sequencing
August 31, 2011 / Clinical Sequencing News - Cyprus' NIPD Genetics Validates Updated Trisomy 21 Assay; Eyes 2013 Launch for Testing Services
November 29, 2012 / PCR Insider - NIPD Genetics Raises €2.5M to Fund Development of Noninvasive Down Syndrome Dx
October 6, 2011 / PCR Insider - Verinata Licenses Quake Patent, Setting Stage for IP Tussle with Sequenom
September 7, 2011 / Clinical Sequencing News - Building on Trisomy 21 Test, Hong Kong Team Develops Method to Detect T13 and T18
July 6, 2011 / Clinical Sequencing News